Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system

Gendelman, Samantha R.; Lang, David M.

doi:10.1016/j.anai.2013.08.020

Cited by 22 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Odds ratio for improved eczema was 5.35 (95% CI 1.61, 17.77); however, the authors combined very heterogeneous outcomes in meta‐analysis which may not be appropriate , and reported no registered protocol. In another recent systematic review , methodological flaws in existing evidence were identified, and the authors’ conclusions were similar to ours – that rigorous studies are needed. The authors identified five of the twelve trials included in our review, and an additional two that we excluded because they were not RCTs .…”

Section: Discussionmentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review

Tam

Calderón²,

Manikam

et al. 2016

Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review

Tam

Calderón²,

Manikam

et al. 2016

Allergy

View full text Add to dashboard Cite

show abstract

“…77 A recent systematic review with the Grading of Recommendations Assessment, Development and Evaluation system reported improvement in clinical symptoms. 78 Serious methodological shortcomings were noted, such as many dropouts, small study size; incomplete descriptions of randomization, blinding, and allocation concealment; and data analysis not by the intention-to-treat principle. The only SLIT study performed with HDM allergens in children with AD described a positive outcome only in those with mild-to-moderate disease.…”

Section: Admentioning

confidence: 99%

International consensus on allergy immunotherapy

Jutel

Agache

Бонини³

et al. 2015

Journal of Allergy and Clinical Immunology

476

418

View full text Add to dashboard Cite

Allergen immunotherapy (AIT) has been used to treat allergic disease since the early 1900s. Despite numerous clinical trials and meta-analyses proving AIT efficacious, it remains underused and is estimated to be used in less than 10% of patients with allergic rhinitis or asthma worldwide. In addition, there are large differences between regions, which are not only due to socioeconomic status. There is practically no controversy about the use of AIT in the treatment of allergic rhinitis and allergic asthma, but for atopic dermatitis or food allergy, the indications for AIT are not well defined. The elaboration of a wider consensus is of utmost importance because AIT is the only treatment that can change the course of allergic disease by preventing the development of asthma and new allergen sensitizations and by inducing allergen-specific immune tolerance. Safer and more effective AIT strategies are being continuously developed both through elaboration of new allergen preparations and adjuvants and alternate routes of administration. A number of guidelines, consensus documents, or both are available on both the international and national levels. The international community of allergy specialists recognizes the need to develop a comprehensive consensus report to harmonize, disseminate, and implement the best AIT practice. Consequently, the International Collaboration in Asthma, Allergy and Immunology, formed by the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma & Immunology; and the World Allergy Organization, has decided to issue an international consensus on AIT.

show abstract

“…A systematic review using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach reported improvement of clinical symptoms of AD. However, the study also noted the strength of recommendation for use of SIT in patients with AD as weak, pinpointing the need for highquality evidence to support AIT in AD (98). Several studies on sublingual immunotherapy in AD patients bring arguments in favour of AIT as a safe and effective strategy (99)(100)(101).…”

Section: Systemic Immunotherapy In Admentioning

confidence: 99%

Biological therapies for atopic dermatitis: An update�(Review)

Deleanu

Nedelea

2018

Exp Ther Med

View full text Add to dashboard Cite

Severe atopic dermatitis, which affects both adults and children, is a debilitating disorder with a significant decline of patients' quality of life. Although aetiopathogenic factors are currently a topic of study and interpretation, the main features of atopic eczema are skin barrier disturbance and immune dysregulation. Severe refractory disease that fails to improve with conventional therapy may benefit from biologic therapy. Progress in understanding immunopathology of atopic dermatitis have allowed identification of therapeutic molecular targets in the field of biological therapy. We reviewed the different biological treatments with a focus on novel targeted agents:

show abstract

Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system

Cited by 22 publications

References 31 publications

Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review

Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review

International consensus on allergy immunotherapy

Biological therapies for atopic dermatitis: An update�(Review)

Contact Info

Product

Resources

About